Company Overview and News
Shares of New Age Beverages Corp. tumbled on heavy volume, as they extended their pullback from record highs, while Tilray Inc.’s headed for a third straight selloff, as investors continued to adjust their cannabis positions ahead of Canada’s full-legalization next month.
ABRW ACB ALEAF NXTTF DTEA WEED ACBFF CRON NBEV CGC TLRY
General Electric (GE) can't seem to catch a break. This week the company disclosed a flaw in their gas turbine engines. The stock was trying to stage a rally off a multi year bottom but the bad news sent the stock back to $12.17 to close the week.
GEC GE GNE TLRY
iQiyi (NASDAQ:IQ) has been both rewarding and frustrating for me. It was a name that we found early, allowing us to nab IQ stock in the low-$20s. A big move into the $30s felt overdone so we exited the name, only to watch it run past $45 a week or two later.
JD BABA IQ GOOGL GOOG BIDU TLRY
Currently, legal marijuana is one of the most exciting investment sectors. It also appears a resilient sector as well. After demonstrating evidence of being technically overbought, Cronos Group (NASDAQ:CRON) put up a remarkable performance, up 19% in just two days of trading. For the year, CRON stock has gained 70%.
TAP STZ.B ALEAF CRON WEED ABBV STZ CGC TLRY
The chaos at Tesla (NASDAQ:TSLA) continues. Tesla stock finds itself stuck in a trading range as production glitches, management turnover, falling bond prices, and investigations hamper the equity.Still, the stock price remains at a high level despite the turmoil.
CKRGZ CHKVP CHKDH CHKVZ TLRY CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI TSLA GM
2018-09-22 seekingalpha - 2
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
TCBK CAT MET HTH LBCC FIXX CRM BUSE STXB CHFC FIBH FBLV AVGO HBMD CAG SSB ABX MO SBT UMRX PRU MTZ NBHC HOMB EVRI 2914 FFIN BILI OPBK TAP ABRW OZK ACB BREW UNUM OLBK MTN JNJ GHG ALDX BWA VZ FNV EQBK LMT FB JAPAF RAD FNLC AXP 4162 ITYBF PRU CBTX JAPAY PPBI SFNC PNFP TBK CCL KO NCOM NBHOZ CARO TSC BOFIL KBH LION SPPI SMBK PACW DY LTEA BB WSBC TTEC VBTX ABCB DTEA HBNC GNPX FBPRM FBPRL FBPRO XLC FBPRN SNDX CSFL FBPRP MBIN HTWC AZN KMX ACBFF GBCI BATS SIVB KEY BOKF ASNA ABTX HTLF NKE HON TWTR AMAT CELH ROX JBL FBP IMBBY BY CHCO KDP INCY CRON FSB CCL STZ NBEV WTFCW WTFC FBMS WTFCM INTU NBHDZ GOOGL EGBN LTXB STL FBNC BA BB ONB PRGS FBK PFE IMBBF PFBC PH NEM LOXO MNST GOOG PIR RBB TLRY HWC PB BFST NCBS MKC WEED ACN FBSI BBBY DIS BMY OBNK OGE MBNC RNST ABX BOFI CMCSA SNV UBSH WTFPP CGC CADE AZN T IBOC IQ ONE MRK GNTY
2018-09-22 247wallst - 2
Cannabis stocks had a huge showing on Wall Street this past week. In fact, most of the news flow surrounding these stocks had investors pouring money into them. One stock even notched a gain of over 500% at one point in the past week.
STZ.B MJ ALEAF CRON ACBFF DTK MJX NBEV STZ CGC TLRY ACB GWPH WEED LEVB GWP
2018-09-21 thestar - 1
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
LBLCF ACBFF TLRY MFC ACB 0945 APH MFC APHQF
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET